Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

Journal of Gastroenterology

Volumn 38, Issue 2, 2003, Pages 158-163

  Arase, Yasuji ^a   Ikeda, Kenji ^a   Tsubota, Akihito ^a   Suzuki, Yoshiyuki ^a   Saitoh, Satoshi ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Suzuki, Fumitaka ^a   Akuta, Norio ^a   Someya, Takashi ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; HCV RNA; Prolonged interferon therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILE DUCT CARCINOMA; BIOCHEMISTRY; CHRONIC HEPATITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DNA PROBE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TIME; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0037299204     PISSN: 09441174     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005350300026     Document Type: Article

References (21)

1. Tsubota A, Chayama K, Ikeda K, Arase Y, Koida I, Saitoh S, et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994;19:1088-94.
2. Yoshioka K, Kakum S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
3. Hagiwara H, Hayashi N, Mita E, Ueda K, Takehara T, Kasahara A, et al. Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-α. Hepatology 1992;15:37-41.
4. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind placebo-controlled trial. N Engl J Med 1989;321:1506-10.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
6. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. Hepatology 1991;13:1040-3.
7. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, et al. Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: a multicenter randomized controlled trial. Hepatology 1995:21:291-7.
8. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier G, Trepo G, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
9. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-α 2b for 60 weeks. Hepatology 1994;19:280-5.
10. Saracco G, Borghesio E, Mesina P, Solinas A, Spezia C, Macor F, et al. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon α-2b for chronic hepatitis type C. J Hepatol 1997;27:56-62.
11. Enomoto N, Sakuma I, Asahina Y, Kurasaki M, Musakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-30.
12. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
13. Hashimoto M, Chayama K, Tsubota A, Kobayashi M, Nakano A, Takagi K, et al. Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region. Int Hepatol Commun 1996;4:263-7.
14. Arase Y, Ikeda K, Chayama K, Murashima N, Tsubota A, Suzuki Y, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C. J Gastroenterol 2000;35:221-5.
15. Dusheiko G, Schmilovitzs-Weiss H, Brown D, McOmish F, Yap P-I, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8.
16. Mellor J, Holmes EC, Jarivis LM, Yap PL, Simmonds P, and The International HCV Collaborative Study Group. Investigation of the pattern of hepatitis C virus sequence diversity in different geographical regions: implications for virus classification. J Gen Virol 1995;76:2423-507.
17. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, et al. Accurate quantification of heptatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996;34:901-7.
18. Lunel F, Cresta P, Vitour D, Payan C, Dumont B, Frangeul L, et al. Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assay. Hepatology 1999;29:528-35.
19. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-20.
20. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
21. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, Albrecht J. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000;32:1131-7.